The company's growth has been driven by an expanding specialty portfolio, strong India business growth, a robust product pipeline and value-accretive acquisitions. Zydus maintains India's largest biosimilar portfolio with more than 13 biosimilars developed and manufactured domestically. The company expects its India formulations business to outperform the pharmaceutical market by 200-400 basis points, positioning it as a competitive player in high-growth domestic and international segments.
Cyborg Score Rationale
Zydus reported Q3 2026 revenue of ₹68.6b, up 30% from Q3 2025, and Q2 2026 net income of ₹12.6b, up 38% from Q2 2025. Recent product launches including ANYRA™ biosimilar and strategic acquisitions strengthen its competitive position, though revenue is forecast to grow 6.1% annually over the next 3 years, compared to a 10% growth forecast for the Indian pharmaceutical industry.
Top Insights
In February 2026, Zydus launched ANYRA™, India's first indigenously developed Aflibercept 2 mg biosimilar, strengthening its ophthalmic biosimilar portfolio.
In 2025, Zydus acquired the CDMO business of Agenus including their two biologics manufacturing sites in Emeryville and Berkeley, expanding US manufacturing capacity.
Zydus Therapeutics reported positive topline results for Saroglitazar in the EPICS-III Phase 2(b)/3 trial for Primary Biliary Cholangitis, with a US regulatory submission planned for early 2026.
The US FDA has granted priority review to Saroglitazar, Zydus Lifesciences' drug for treating Primary Biliary Cholangitis, de-risking the regulatory pathway for this differentiated product.
Named Competitors
Torrent Pharmaceuticals — Integrated pharmaceutical manufacturer focusing on generics and specialty drugs
Mankind Pharma — Leading domestic pharmaceutical company with focus on generics
Ajanta Pharma — Diversified pharmaceutical manufacturer across formulations and APIs
Natco Pharma — Generics and active pharmaceutical ingredients manufacturer
Glenmark Pharmaceuticals — Specialty and generic pharmaceuticals company with global reach
Recent Developments
(June 2026) Stock gained 20% over prior month; company raised FY27 earnings estimates driven by strong India business growth and specialty portfolio expansion
(May 2026) Board approved increased share buyback price from ₹1,150 to ₹1,260 per share; Q4 FY26 net profit reported at ₹1,272.5 crore, up 8.7% YoY
(February 2026) Launched ANYRA™, India's first indigenously developed Aflibercept 2 mg biosimilar for retinal conditions
(January 2026) Completed acquisition of Agenus' CDMO business with two biologics manufacturing sites in California
Open the full interactive Zydus Lifesciences Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.